Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Veru-944 · 1 trial · 1 indication
Percentage of change in frequency of moderate to severe hot flashes at 6 weeks
| Arm | Type | Description |
|---|---|---|
| Veru-944 10 mg | EXPERIMENTAL | Veru-944 10 mg daily |
| Veru-944 50 mg | EXPERIMENTAL | Veru-944 50 mg daily |
| Placebo | PLACEBO_COMPARATOR | Placebo daily |
| Name | Type | Description |
|---|---|---|
| Veru-944 | DRUG | Treat hot flashes (vasomotor symptoms) in men with advanced prostate cancer on ADT |
| Placebo | DRUG | Placebo |
Inclusion Criteria 1. Be over 18 years of age; 2. Be able to communicate effectively with the study personnel; 3. Have histologically confirmed prostate cancer; 4. Have been treated with an LHRH agonist or LHRH antagonist for at least the 3 months prior to randomization; 5. Be continued on an LHRH ...
Top 20 of 53 competitors
Veru-944 is an investigational small molecule being studied for use in men with metastatic prostate cancer. In clinical testing, it was evaluated for its ability to ameliorate hot flashes in men with advanced prostate cancer. It is not approved and remains in clinical development.
The molecular target of Veru-944 has not been disclosed in available clinical trial information. The drug is a small molecule being investigated for its effect on hot flashes in men with metastatic prostate cancer, but its specific mechanism of action has not been publicly detailed.
Veru-944 is being developed by Veru Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol VERU. The company is conducting clinical research on this investigational drug for prostate cancer-related symptoms.
Veru-944 is in Phase 2 clinical development. A Phase 2 study of the drug has been completed, evaluating its effects on hot flashes in men with advanced prostate cancer. The drug is investigational and has not received FDA approval.
Veru-944 has one completed Phase 2 clinical trial, identified as NCT03646162. This randomized, double-blind, placebo-controlled study enrolled 93 men with metastatic prostate cancer in the United States to evaluate the drug's effect on hot flashes.
No alternative names for Veru-944 have been reported in clinical trial records. The drug is identified solely as Veru-944 in the available study information, and no other names or aliases have been associated with it.